source
- Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric eventsXenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…
- Electra Therapeutics raises $350M in IPO to fund pivotal immune-disease antibody developmentElectra Therapeutics announced an initial public offering that raised $350 million, exceeding its earlier target. The IPO consisted of 23.3 million shares sold at $15 per share, and underwriters w…